<DOC>
	<DOCNO>NCT00476034</DOCNO>
	<brief_summary>This 39-week , active control , study design ass long-term efficacy , safety tolerability lumiracoxib 100mg od patient osteoarthritis ( OA ) knee participate 13-week core CCOX189A2361 study .</brief_summary>
	<brief_title>Efficacy Safety Lumiracoxib Patients With Primary Knee Osteoarthritis ( OA )</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Any patient complete core study 2361 may enter extension trial upon sign informed consent . A patient define complete he/she complete core study 2361 include Visit 6 ( week 13 ) without major protocol violation . Those patient continue treatment extension study consider appropriate treating physician Those patient noncompliant demonstrated major protocol violation core study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>lumiracoxib</keyword>
	<keyword>celecoxib</keyword>
	<keyword>Cox-2</keyword>
	<keyword>knee</keyword>
</DOC>